摘要
目的探讨含雷替曲塞/贝伐珠单抗的联合化疗方案在晚期结直肠癌二线及二线以上治疗中的疗效及安全性。方法收集二线或二线以上治疗均采用含雷替曲塞/贝伐珠单抗联合伊立替康或奥沙利铂方案共15例晚期结直肠癌患者的资料,所有方案均以2周为1周期,其中采用雷替曲塞+贝伐珠单抗方案2例,雷替曲塞+贝伐珠单抗+伊立替康方案9例,雷替曲塞+贝伐珠单抗+奥沙利铂方案4例。贝伐珠单抗5mg/kg静滴,d1;雷替曲塞2mg/m2静滴15min,d2;伊立替康180mg/m2静滴1h,d2;奥沙利铂85mg/m2静滴2h,d2。结果 15例患者均可评价疗效。获PR 2例,SD 10例,PD 3例,有效率为13.3%,疾病控制率为80.0%;中位无疾病进展时间为5.1个月(95%CI:3.404～6.813个月),中位OS为11.5个月(95%CI:8.985～13.930个月)。毒副反应主要包括食欲减退、恶心呕吐、疲乏、白细胞减少和血小板减少等,3～4级毒副反应以食欲减退、恶性呕吐、疲乏和血小板减少为主。结论含雷替曲塞/贝伐珠单抗联合伊立替康或奥沙利铂方案在晚期结直肠癌二线及二线以上治疗中的疾病控制率高,毒副反应可耐受,可推荐为Ⅲ期临床研究方案以及二线或二线以上晚期结直肠癌的治疗方案。
Objective To investigate the efficacy and safety of raltitrexed/bevacizumab in combination with irinotecan or oxaliplation for advanced colorectal cancer as the second-line and second-line above treatment. Methods Fifteen cases of advanced colorectal cancer were enrolled to receive regimens including rahitrexed/bevacizumab combined with irinotecan or oxaliplation. Two cases were treated with raltitrexed ＋ bevacizumab regimen, 9 cases with rahitrexed ＋ bevacizumab ＋ irinotecan regimen, and 4 cases with raltitrexed ＋ bevacizumab ＋ oxaliplatin regimen. The doses of the drugs were as follows： bevacizumab 5mg/kg iv, d1; raltitrexed 2mg/m^2iv 15min, d2; irinotecan 180mg/m^2iv lh, d2; and oxaliplatin 85mg/m^2iv 2h d2. Two weeks was a cycle for each regimen. Results The efficacy of the 15 patients could be evaluated. Two cases were in PR, 10 cases in SD, 3 cases in PD, the response rate was 13.3%, and the disease control rate was 80.0%. The median progress-free survival was 5.1 months（95% CI： 3. 404-6. 813 months）, and the median overall survival was 11.5 months（95% CI： 8. 985-13. 930 months）. The adverse effect included anorexia, nausea/vomiting, fatigue, leukopenia, thrombocytopenia, ere. , and the main 3-4 grade adverse effects were anorexia, nausea/vomiting, fatigue, and thrombocytopenia. Conclusion Raltitrexed/bevacizumab combined with irinotecan or oxaliplatin as the second-line and second-line above treatment for advanced colorectal cancer has high disease control rates, and the adverse effect is well tolerated. The combined regimen can be recommended as a phase Ⅲ clinical research and second-line and second-line above treatment for advanced colorectal cancer.
出处
《临床肿瘤学杂志》
CAS
2013年第1期70-73,共4页
Chinese Clinical Oncology
